Lead Product(s): Somapacitan
Therapeutic Area: Genetic Disease Product Name: Sogroya
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Recommendation for marketing authorisation for Sogroya is based on results from the Phase III REAL 1 clinical trial programme, which investigated the efficacy and safety of Sogroya in AGHD.